Pyrazolo-heteroaryl TLR7 Agonists with Selective Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current TLR7 agonists lack selectivity for TLR7 over TLR8, leading to potential severe side effects due to over-secretion of TNF-α, and have limitations in therapeutic effectiveness and safety.
Innovation Solution
Development of novel pyrazolo-heteroaryl derivatives that act as selective TLR7 agonists with a lower onset concentration, improved selectivity for TLR7, and minimal activation of TLR8, while having a weak inhibitory effect on CYP enzymes, enhancing therapeutic efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TLR7 agonists are used to treat viral infections, then therapeutic effectiveness is improved, but selectivity for TLR7 over TLR8 deteriorates leading to severe side effects from TNF-α over-secretion
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at defined positions on the pyrazolo-pyrimidine core structure. Different substituents (R1-R6) are placed at specific locations to create localized interactions that preferentially bind to TLR7 over TLR8, achieving selectivity while maintaining antiviral therapeutic effectiveness.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters including substituent types, positions, and molecular properties of the pyrazolo-pyrimidine derivatives. These parameter modifications optimize the balance between TLR7 activation potency and TLR8 selectivity, reducing harmful TNF-α over-secretion while preserving therapeutic efficacy.
2Reliability
If TLR7 agonist activity is increased to improve antiviral效果, then therapeutic effectiveness is improved, but CYP enzyme inhibition increases causing safety issues
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional regions: the pyrazolo-pyrimidine core responsible for TLR7 agonist activity, and separately selected substituent groups (R1-R6) that modulate metabolic stability. This segmentation allows optimization of antiviral effectiveness while minimizing CYP enzyme inhibition through careful substituent selection.
Solution Approach 2:
The patent uses intermediary principles by introducing specific substituent groups that act as mediators between the active core structure and metabolic enzymes. These intermediaries (specific R groups) reduce direct interaction between the drug and CYP enzymes while preserving TLR7 agonist activity, thereby improving safety.
3Reliability
If pyrazolo-pyrimidine derivatives are developed for TLR7 activation, then therapeutic effectiveness is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies universality by designing a core pyrazolo-pyrimidine structure that serves multiple functions: TLR7 agonist activity, metabolic stability, and manageable synthesis. This universal core can accommodate various substituents (R1-R6) to create multiple derivatives with different pharmacological profiles, reducing the need for entirely new molecular scaffolds and simplifying manufacturing.
Data Source
AI summary
Disclosed are a pyrazolo-heteroaryl derivative, a preparation method and medical use thereof. In particular, the present invention relates to a new pyrazolo-heteroaryl derivative as shown in the general formula (I), a preparation method thereof and a pharmaceutical composition containing the derivative and the use thereof as a therapeutic agent, in particular as a TLR7 agonist, wherein each substituent in the general formula (I) is defined in the description.